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Table SI-1. Coupling of N-Fmoc-protected amino acids with N-sulfanylethylcoumarin linker 3 
 
Fmoc-Xaa-OH reaction time (h) product isolated yield (%) 
Gly 6 8a 95 
Ala 18 8b 93 
Asp(Ot-Bu) 24 8c 60* 
Glu(Ot-Bu) 6 8d 78 
Asn(Trt) 6 8e 87 
Gln(Trt) 6 8f 83 
Ser(t-Bu) 6 8g 87 
Thr(t-Bu) 6 8h 84 
Cys(Trt) 6 8i 79 
Pro 24 8j 48** 
Val 6 8k 86 
Met 6 8l 83 
Leu 6 8m 91 
Ile 6 8n 85 
Tyr(t-Bu) 6 8o 73 
Phe 6 8p 81 
His(MBom#) 6 8q 70 
Lys(Boc) 6 8r 70 
Arg(Pbf) 12 8s 74 
Trp 6 8t 87 
#4-methoxybenzyloxymethyl.S1  
*Recovery of substrate: 24%. **Recovery of substrate: 43%. 
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Figure SI-1. HPLC chart of crude model SECmide peptide. Analytical HPLC conditions: Cosmosil 
5C18 AR-II column (4.6 × 250 mm) with a linear gradient of 0.1% (v/v) TFA–MeCN in 0.1% (v/v) 
TFA aq. (1:99–30:70 over 30 min) at a flow rate 1.0 mL/min, detection at 220 nm. 
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Figure SI-2. HPLC monitoring of N–S acyl transfer of SECmide peptide in 0.1% (v/v) TFA–MeCN: 
0.1% (v/v) TFA aq. (1:4, (v/v)). Analytical HPLC conditions: Cosmosil 5C18 AR-II column (4.6 × 250 
mm) with a linear gradient of 0.1% (v/v) TFA–MeCN in 0.1% (v/v) TFA aq. (1:99–30:70 over 30 min) 
at a flow rate 1.0 mL/min, detection at 220 nm. *Internal standard (benzenesulfonic acid). 
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Figure SI-3. HPLC monitoring of preparation of peptide thioester 13. Analytical HPLC conditions:  
Cosmosil 5C18 AR-II column (4.6 × 250 mm) with a linear gradient of 0.1% (v/v) TFA–MeCN in 0.1% 
(v/v) TFA aq. (1:99–30:70 over 30 min) at a flow rate 1.0 mL/min, detection at 220 nm.  
*MPA. 
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Figure SI-4. HPLC monitoring of preparation of peptide thioester 15. Analytical HPLC conditions: 
Cosmosil 5C18 AR-II column (4.6 × 250 mm) with a linear gradient of 0.1% (v/v) TFA–MeCN in 0.1% 
(v/v) TFA aq. (10:90–30:70 over 30 min) at a flow rate 1.0 mL/min, detection at 220 nm.  
*Nonpeptidic compounds. **Internal standard (benzenesulfonic acid). 
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Figure SI-5. Verification of epimerization of C-terminal chiral amino acids during N–S acyl transfer 
mediated thioesterification. a) Peptide thioester 15 obtained via N–S acyl transfer of SECmide 
peptide 14. b) Reference peptide thioesters S4 and S5 prepared using Boc SPPS. Analytical HPLC 
conditions: Cosmosil 5C18 AR-II column (4.6 × 250 mm) with a linear gradient of 0.1% (v/v) TFA–
MeCN in 0.1% (v/v) TFA aq. (10:90–30:70 over 30 min) at a flow rate 1.0 mL/min, detection at 220 
nm. Only a critical retention time region of the HPLC charts was enlarged. *Substrate 14. 
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Figure SI-6. Exploration of N–S acyl transfer promoters of SECmide peptide 11. 
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Figure SI-7-1. HPLC monitoring of NCL of SECmide or SEAlide peptide with N-terminal cysteinyl 
peptide. a) NCL condition: Table 2 entry 2, b) NCL condition: Table 2 entry 5, c) NCL condition: 
Table 2 entry 8, d) NCL condition: Table 2 entry 11. Analytical HPLC condition for a): Cosmosil 
5C18-AR-II analytical column (4.6 × 250 mm) with a linear gradient of solvent B in solvent A, 1% to 
30% over 30 min. Analytical HPLC conditions for b), c) or d): Cosmosil 5C18-AR-II analytical 
column (4.6 × 250 mm) with a linear gradient of solvent B in solvent A, 5% to 35% over 30 min. 
*Nonpeptidic compounds. 
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Figure SI-7-2. Verification of Epimerization of C-terminal chiral amino acids during NCL. a) 
Ligation product 19 obtained NCL between SECmide peptide 14 and N-terminal cysteinyl peptide 
17. b) Reference peptide S6 or S7 prepared NCL between peptide thioester S2 or S3 and N-terminal 
cysteinyl peptide 17. Analytical HPLC conditions: Cosmosil 5C18-AR-II analytical column (4.6 × 
250 mm) with a linear gradient of solvent B in solvent A, 5% to 35% over 30 min. Only a critical 
retention time region of the HPLC charts was enlarged. *Nonpeptidic compounds. 
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General Methods 
 
Reactions except for peptide synthesis were carried out under a positive pressure of argon. Mass 
spectra were recorded on a Waters MICROMASS® LCT PREMIERTM (ESI-TOF). For HPLC 
separation, a Cosmosil 5C18-AR-II analytical column (Nacalai Tesque, 4.6 × 250 mm, flow rate 1.0 
mL/min), a Cosmosil 5C18-AR-II semi-preparative column (Nacalai Tesque, 10 × 250 mm, flow rate 
3.0 mL/min), or a Cosmosil 5C18-AR-II preparative column (Nacalai Tesque, 20 × 250 mm, flow rate 
10 mL/min) was employed, and eluting products were detected by UV at 220 nm. A solvent system 
consisting of 0.1% TFA aqueous solution (v/v, solvent A), 0.1% TFA in MeCN (v/v, solvent B), 10 
mM aqueous ammonium acetate (pH 6.7) (solvent C) and MeCN (solvent D) was used for HPLC 
elution. For column chromatography, silica gel (KANTO KAGAKU N-60) was employed. Thin layer 
chromatography was performed on precoated plates (0.25 nm, silica gel Merck KGaA 60 F245). NMR 
spectra were recorded using Bruker AV400N at 400 MHz frequency for 1H, and JEOL JNM-AL300 
at 75 MHz frequency for 13C. The fluorescence intensity (FI) was measured on a Perkin Elmer 
Enspire® Multimode Plate Reader with an excitation wavelength of 373 nm and an emission 
wavelength of 465 nm (microplate: FlUOTRACTM 600 (Greiner Bio-One)). 
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Preparation of N-sulfanylethylcoumarin linker 3 
 
[2-(7-aminocoumarin-4-acetylamino)]-acetic acid allyl ester (5) 
 
 
 
 
 
To a solution of H-Gly-OAllylHCl (10.3 g, 68.2 mmol) in DMF (150 mL) was slowly added DIPEA 
(24.3 mL, 141 mmol) at an ice-salt bath temperature. The resulting solution was stirred for 15 min. 
Then, 4 (9.96 g, 45.4 mmol), DMAP (5.55 g, 45.4 mmol) and EDCHCl (13.1 g, 68.2 mmol) were 
added and the mixture was warmed up to room temperature and stirred for another 16 h. After removal 
of the solvent in vacuo, water was added to the residual mixture. The yellow precipitate was collected 
by filtration and washed with water to afford 5 (12.0 g, 37.9 mmol, 83%) as a yellow powder: 1H NMR 
(DMSO-d6, 400 MHz)  = 3.63 (2H, s), 3.91 (2H, d, J = 5.9 Hz), 4.57 (2H, ddd, J = 5.2, 1.5 and 1.5 
Hz), 5.20 (1H, ddt, J = 10.6, 1.5 and 1.5 Hz), 5.30 (1H, ddt, J = 17.2, 1.5 and 1.5 Hz), 5.88 (1H, ddt, 
J = 17.2, 10.6 and 5.2 Hz), 5.99 (1H, s), 6.13 (2H, s), 6.41 (1H, d, J = 2.2 Hz), 6.54 (1H, dd, J = 8.7 
and 2.2 Hz), 7.42 (1H, d, J = 8.7 Hz), 8.67 (1H, t, J = 5.9 Hz); 13C NMR (DMSO-d6, 75 MHz)  = 
38.4, 40.9, 64.8, 98.5, 108.2, 108.7, 111.1, 117.9, 126.3, 132.3, 151.1, 153.0, 155.6, 160.7, 168.6, 
169.4; HRMS (ESI-TOF) m/z calcd for C16H16N2NaO5 ([M + Na]+) 339.0957, found 339.0935. 
 
{2-[7-N-(2-nitrobenzenesulfonylamino)coumarin-4-acetylamino]}-acetic acid allyl ester (6)S2 
 
 
 
 
 
To a solution of compound 5 (4.00 g, 12.6 mmol) in pyridine (63 mL) was added 2-
Nitrobenzenesulfonyl chloride (5.61 g, 25.3 mmol). The reaction mixture was stirred at room 
temperature for 5 h. After, removal of the solvent in vacuo followed by addition of 5% (w/v) KHSO4 
aq, the resulting mixture was extracted with EtOAc. The organic phase was washed with 5% (w/v) 
KHSO4 aq. followed by brine, filtered and concentrated in vacuo. The residue was purified by column 
chromatography (CHCl3/MeOH  100/0 to 100/7 then 0/100 (v/v)) to yield 6 (4.84g, 9.65 mmol, 77%) 
as a pale orange powder: 1H NMR (DMSO-d6, 400 MHz)  = 3.72 (2H, s), 3.89 (2H, d, J = 5.9 Hz), 
4.54 (2H, ddd, J = 5.3, 1.5 and 1.5 Hz), 5.17 (1H, ddt, J = 10.6, 1.5 and 1.5 Hz), 5.27 (1H, ddt, J = 
17.2, 1.5 and 1.5 Hz), 5.85 (1H, ddt, J = 17.2, 10.6 and 5.3 Hz), 6.36 (1H, s), 7.05-7.12 (2H, m), 7.68 
S13 
(1H, d, J = 8.4 Hz), 7.82-7.92 (2H, m), 8.01-8.04 (1H, m), 8.07-8.11 (1H, m), 8.68 (1H, t, J = 5.9 Hz), 
11.44 (1H, s); 13C NMR (DMSO-d6, 75 MHz)  = 38.2, 40.9, 64.8, 105.6, 114.4, 114.7, 115.1, 117.8, 
124.9, 126.8, 129.9, 130.9, 132.2, 132.9, 135.1, 140.3, 147.9, 150.3, 153.7, 159.5, 168.2, 169.3; HRMS 
(ESI-TOF) m/z calcd for C22H19KN3O9S ([M + K]+) 540.0479, found 540.0473. 
 
(2-{7-[N-(2-nitrobenzenesulfonyl)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-
acetic acid allyl ester (7) 
 
 
 
 
 
To a stirred suspension of compound 6 (663 mg, 1.32 mmol), triphenylmethyl-sulfanylethyl alcohol 
(846 mg, 2.64 mmol) and Ph3P (692 mg, 2.64 mmol) in THF (25 mL) was added 40% (v/v) 
DEAD/toluene (1.20 mL, 2.64 mmol) at 0 °C. After being stirred at room temperature for 17 h, the 
reaction mixture was diluted with EtOAc, sat. NH4Cl aq. The solution was extracted with EtOAc, 
washed with sat. NH4Cl aq., brine, dried over NaSO4, filtered and concentrated. The residue was 
purified by column chromatography (hexane/EtOAc  1/2 to 1/4 (v/v)) then (CH2Cl2/ EtOAc  5/2 
(v/v)) to yield 7 (614 mg, 0.764 mmol, 58%) as orange amorphous solid: 1H NMR (DMSO-d6, 400 
MHz)  = 2.18 (2H, t, J = 6.9 Hz), 3.68 (2H, t, J = 6.9 Hz), 3.84 (2H, s), 3.96 (2H, d, J = 5.9 Hz), 4.54 
(2H, ddd, J = 5.3, 1.5 and 1.5 Hz), 5.17 (1H, ddt, J = 10.6, 1.5 and 1.5 Hz), 5.28 (1H, ddt, J = 17.2, 
1.5 and 1.5 Hz), 5.86 (1H, ddt, J = 17.2, 10.6 and 5.3 Hz), 6.56 (1H, s), 7.09 (1H, dd, J = 8.5 and 2.2 
Hz), 7.11-7.26 (16H, m), 7.70 (1H, dd, J = 8.0 and 1.3 Hz), 7.73-7.81 (2H, m), 7.88 (1H, td, J = 8.0 
and 1.3 Hz), 9.96 (1H, dd, J = 8.0 and 1.3 Hz), 8.81 (1H, t, J = 5.9 Hz); 13C NMR (DMSO-d6, 75 
MHz)  = 29.8, 38.2, 40.9, 49.5, 64.8, 66.2, 116.0, 116.4, 117.8, 118.6, 124.3, 124.5, 126.0, 126.6, 
127.9, 128.9, 129.4, 130.4, 132.2, 132.3, 135.2, 139.6, 144.0, 147.6, 150.1, 153.0, 159.2, 168.1, 169.3; 
HRMS (ESI-TOF) m/z calcd for C43H37KN3O9S2 ([M + K]+) 842.1608, found 842.1626. 
 
(2-{7-[N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid allyl ester (3) 
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To a solution of compound 7 (4.90 g, 6.10 mmol) in MeCN (50 mL) were added K2CO3 (1.68 g, 12.2 
mmol) and thiophenol (3.11 ml, 30.5 mmol) at 0 °C. The resulting solution was stirred for 15 min. 
Then the mixture was warmed up to room temperature and stirred for another 12 h. After evaporation, 
hexane was added to the residual mixture. The yellow precipitate was collected by filtration and 
washed with hexanes. The residue was dissolved in CHCl3 and THF, and concentrated in vacuo. The 
residue was purified by column chromatography (hexane/EtOAc  1/1 to 1/2 then 0/100 (v/v), and 
THF) to yield 3 (3.15 g, 5.09 mmol, 84%) as a pale yellow powder: 1H NMR (DMSO-d6, 400 MHz) 
= 2.38 (2H, t, J = 6.7 Hz), 3.04 (2H, dt, J = 6.7 and 6.7 Hz), 3.65 (2H, s), 3.92 (2H, d, J = 5.9 Hz), 
4.57 (2H, ddd, J = 5.3, 1.5 and 1.5 Hz), 5.20 (1H, ddt, J = 10.6, 1.5 and 1.5 Hz), 5.30 (1H, ddt, J = 
17.2, 1.5 and 1.5 Hz), 5.88 (1H, ddt, J = 17.2, 10.6 and 5.3 Hz), 6.02 (1H, s), 6.24 (1H, d, J = 2.1 Hz), 
6.43 (1H, dd, J = 8.8 and 2.1 Hz), 6.74 (1H, t, J = 6.7 Hz), 7.22-7.36 (15H, m), 7.43 (1H, d, J = 8.8 
Hz), 8.68 (1H, t, J = 5.9 Hz); 13C NMR (DMSO-d6, 75 MHz) = 30.7, 38.4, 40.9, 41.2, 64.8, 66.3, 96.5, 
108.4, 108.9, 110.0, 117.9, 126.1, 126.8, 128.0, 129.1, 132.3, 144.4, 151.0, 151.6, 155.7, 160.6, 168.5, 
169.4; HRMS (ESI-TOF) m/z calcd for C37H34KN2O5S ([M + K]+) 657.1826, found 657.1829. 
 
Preparation of Fmoc-Xaa-N-sulfanylethylcoumarin 8 
 
Typical procedure of coupling of Fmoc-Xaa-OH with 3 
To a stirred solution of compound 3 (300 mg, 0.480 mmol) in THF (15 mL) were added Fmoc-Gly-
OH (721 mg, 2.42 mmol), DIPEA (422 L, 2.42 mmol) and POCl3 (226 L, 2.42 mmol) at 0 °C. After 
being stirred at 50 °C for 6 h, the reaction was quenched by the addition of sat. NaHCO3 aq. After 
extraction with EtOAc, the obtained organic layer was washed with sat. NaHCO3 aq., water, sat. 
NH4Cl aq., and brine. The obtained solution was dried over Na2SO4 and evaporated in vacuo. The 
product was purified by column chromatography (CH2Cl2/ EtOAc  5/1 to 5/2 (v/v)) to yield 8a (414 
mg, 0.461 mmol, 95%) as white amorphous solid. 
 
(2-{7-[N-(Fmoc-Gly)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid allyl 
ester (8a) 
 
 
 
 
 
 
White amorphous solid; yield: 95% (414 mg); 1H NMR (CDCl3, 400 MHz)  = 2.41 (2H, t, J = 7.3 
Hz), 3.51 (2H, br t, J = 7.3 Hz), 3.61 (2H, br s), 3.75 (2H, s), 4.08 (2H, d, J = 5.2 Hz), 4.18 (1H, t, J = 
S15 
7.1 Hz), 4.31 (2H, d, J = 7.1 Hz), 4.63 (2H, d, J = 5.9 Hz), 5.25 (1H, ddt, J = 10.6, 1.2 and 1.1 Hz), 
5.31 (1H, br ddt, J = 17.2, 1.2 and 1.2 Hz), 5.67 (1H, br t, J = 4.3 Hz), 5.88 (1H, ddt, J = 17.1, 10.6 
and 5.9 Hz), 6.44-6.54 (2H, m), 6.89-7.00 (2H, m), 7.11-7.41 (19H, m), 7.57 (2H, d, J = 7.4 Hz), 7.67 
(1H, d, J = 8.4 Hz), 7.75 (2H, d, J = 7.5 Hz); 13C NMR (CDCl3, 75 MHz)  = 29.6, 40.0, 41.7, 43.7, 
47.2, 49.0, 66.4, 67.3, 116.9, 117.9, 119.2, 119.4, 120.1, 124.3, 125.2, 126.9, 127.2, 127.8, 128.0, 
129.6, 131.4, 141.4, 143.2, 143.9, 144.5, 148.3, 154.4, 156.2, 159.6, 167.4, 167.8, 169.3; HRMS (ESI-
TOF) m/z calcd for C54H47KN3O8S ([M + K]+) 936.2721, found 936.2723. 
 
(2-{7-[N-(Fmoc-L-Ala)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid 
allyl ester (8b) 
 
 
 
 
 
 
White amorphous solid; yield: 93% (206 mg); []26D 89.6 (c 1.03, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 1.12 (3H, br d, J = 6.0 Hz), 2.25-2.38 (1H, m), 2.45-2.59 (1H, m), 3.32-3.43 (1H, m), 3.47-
3.59 (1H, m), 3.72 (1H, d, J = 15.7 Hz), 3.78 (1H, d, J = 15.7 Hz), 3.74 (2H, m), 4.09 (2H, d, J = 5.3 
Hz), 4.18 (2H, m), 4.31 (2H, d, J = 7.1 Hz), 4.63 (2H, d, J = 6.0 Hz), 5.26 (1H, ddt, J = 10.7, 1.2 and 
1.2 Hz), 5.32 (1H, ddt, J = 17.0, 1.2 and 1.2 Hz), 5.49 (1H, br d, J = 7.8 Hz), 5.88 (1H, ddt, J = 17.0, 
10.7 and 6.0 Hz), 6.35 (1H, br t, J = 5.3 Hz), 6.48 (1H, s), 6.97-7.05 (2H, m), 7.08-7.42 (19H, m), 7.57 
(1H, d, J = 7.0 Hz), 7.59 (1H, d, J = 7.0 Hz), 7.65 (1H, d, J = 8.4 Hz), 7.76 (2H, d, J = 7.5 Hz); 13C 
NMR (CDCl3, 75 MHz)  = 19.1, 29.4, 39.9, 41.7, 47.2, 47.8, 49.4, 66.4, 67.1, 67.2, 116.9, 117.7, 
118.9, 119.4, 120.1, 124.6, 125.3, 126.5, 126.8, 127.2, 127.8, 128.0, 129.6, 131.3, 141.4, 141.4, 143.9, 
144.0, 144.1, 144.6, 148.3, 154.3, 155.6, 159.7, 167.4, 169.3, 172.6; HRMS (ESI-TOF) m/z calcd for 
C55H49N3NaO8S ([M + Na]+) 934.3138, found 934.3163. 
 
[2-(7-{N-[Fmoc-L-Asp(Ot-Bu)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-acetic 
acid allyl ester (8c) 
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White amorphous solid; yield: 60% (146 mg); []22D 46.5 (c 1.01, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 1.38 (9H, s), 2.26-2.60 (4H, m), 3.45 (2H, br t, J = 7.0 Hz), 3.65 (1H, d, J = 16.8 Hz), 3.69 
(1H, d, J = 16.8 Hz), 4.06 (2H, d, J = 5.2 Hz), 4.13 (1H, t, J = 6.7 Hz), 4.17-4.30 (2H, br m), 4.47 (1H, 
br s), 4.62 (2H, d, J = 5.9 Hz), 5.26 (1H, ddt, J = 10.4, 1.3 and 1.3 Hz), 5.32 (1H, ddt, J = 17.1, 1.3 
and 1.3 Hz), 5.53 (1H, br d, J = 8.4 Hz), 5.88 (1H, ddt, J = 17.1, 10.4 and 5.9 Hz), 6.24 (1H, br t, J = 
5.2 Hz), 6.44 (1H, s), 6.95-7.06 (1H, m), 7.00 (1H, S), 7.08-7.36 (17H, m), 7.39 (1H, t, J = 7.2 Hz), 
7.40 (1H, t, J = 7.5 Hz), 7.51-7.61 (1H, m), 7.55 (2H, d, J = 8.0 Hz), 7.76 (2H, d, J = 7.3 Hz); 13C 
NMR (CDCl3, 75 MHz)  = 28.1, 29.3, 38.4, 39.9, 41.7, 47.2, 49.1, 49.7, 66.4, 67.2, 81.6, 116.9, 117.6, 
118.7, 119.4, 120.1, 124.6, 125.2, 126.3, 126.8, 127.2, 127.3, 127.9, 128.0, 129.7, 131.4, 141.4, 143.8, 
143.9, 144.1, 144.6, 148.2, 154.2, 155.3, 159.7, 167.4, 169.3, 169.3, 170.1; HRMS (ESI-TOF) m/z 
calcd for C60H57N3NaO10S ([M + Na]+) 1034.3662, found 1034.3634.  
 
[2-(7-{N-[Fmoc-L-Glu(Ot-Bu)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-acetic 
acid allyl ester (8d) 
 
 
 
 
 
 
 
White amorphous solid; yield: 78% (194 mg); []22D 89.4 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 1.36 (9H, s), 1.67-1.80 (2H, br m), 2.06-2.17 (2H, br m), 2.25-2.36 (1H, br m), 2.45-2.59 
(1H, br m), 3.29-3.42 (1H, br m), 3.50-3.61 (1H, m), 3.72 (1H, d, J = 15.8 Hz), 3.77 (1H, d, J = 15.8 
Hz), 4.09 (2H, d, J = 5.2 Hz), 4.13-4.22 (2H, m), 4.31 (2H, d, J = 7.1 Hz), 4.64 (2H, d, J = 5.9 Hz), 
5.26 (1H, ddt, J = 10.6, 1.3 and 1.3 Hz), 5.32 (1H, ddt, J = 17.0, 1.3 and 1.3 Hz), 5.55 (1H, br d, J = 
8.3 Hz), 5.88 (1H, ddt, J = 17.0, 10.6 and 5.9 Hz), 6.30 (1H, br t, J = 5.2 Hz), 6.48 (1H, s), 6.99-7.08 
(2H, m), 7.09-7.36 (17H, m), 7.39 (2H, t, J = 7.5 Hz), 7.57 (1H, d, J = 6.6 Hz), 7.59 (1H, d, J = 6.6 
Hz), 7.63 (1H, d, J = 8.2 Hz), 7.76 (2H, d, J = 7.5 Hz); 13C NMR (CDCl3, 75 MHz)  = 27.6, 28.2, 
29.3, 30.8, 39.9, 41.8, 47.3, 49.4, 51.3, 66.4, 67.1, 67.2, 80.8, 117.1, 117.7, 118.9, 119.4, 120.1, 124.7, 
125.3, 126.4, 126.8, 127.2, 127.8, 128.0, 129.6, 131.4, 141.4, 143.9, 144.0, 144.6, 148.2, 154.3, 155.9, 
159.7, 167.3, 169.3, 171.2, 172.0; HRMS (ESI-TOF) m/z calcd for C61H59N3NaO10S ([M + Na]+) 
1048.3819, found 1048.3817. 
 
[2-(7-{N-[Fmoc-L-Asn(Trt)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-acetic 
acid allyl ester (8e) 
S17 
 
 
 
 
 
 
White amorphous solid; yield: 87% (387 mg); []26D 5.5 (c 1.04, CHCl3); 1H NMR (CDCl3, 400 MHz) 
 = 2.37 (2H, br t, J = 7.1 Hz), 2.44-2.66 (2H, br m), 3.26-3.56 (4H, m), 3.92 (2H, d, J = 4.9 Hz), 3.97-
4.06 (1H, br m), 4.06-4.21 (2H, br m), 4.49 (1H, br s), 4.57 (2H, d, J = 5.9 Hz), 5.23 (1H, ddt, J = 10.7, 
1.3 and 1.3 Hz), 5.29 (1H, ddt, J = 17.0, 1.3 and 1.3 Hz), 5.62 (1H, br s), 5.85 (1H, ddt, J = 17.0, 10.7 
and 5.9 Hz), 6.23-6.42 (2H, br m), 6.69-6.89 (3H, br m), 7.06-7.42 (35H, m), 7.49 (2H, br d, J = 6.9 
Hz), 7.74 (2H, br d, J = 5.6 Hz); 13C NMR (CDCl3, 75 MHz)  = 29.2, 39.5, 39.8, 41.6, 47.1, 49.8, 
66.2, 67.2, 67.3, 70.8, 116.5, 117.3, 118.5, 119.2, 120.1, 124.4, 125.2, 125.3, 126.1, 126.8, 127.2, 127.3, 
127.9, 128.0, 128.1, 128.8, 129.6, 131.5, 141.3, 141.4, 143.7, 143.8, 144.5, 144.6, 148.3, 154.1, 155.2, 
159.7, 167.6, 168.6, 169.3, 170.2; HRMS (ESI-TOF) m/z calcd for C75H64N4NaO9S ([M + Na]+) 
1219.4292, found 1219.4301. 
 
[2-(7-{N-[Fmoc-L-Gln(Trt)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-acetic 
acid allyl ester (8f) 
 
 
 
 
 
 
 
White amorphous solid; yield: 83% (244 mg); []21D 72.8 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 1.68 (1H, br dt, J = 14.1 and 7.0 Hz), 1.74-1.86 (1H, br m), 2.15 (2H, br t, J = 7.0 Hz), 2.23-
2.36 (1H, br m), 2.42-2.56 (1H, br m), 3.24-3.39 (1H, br m), 3.46-3.63 (1H, br m), 3.58 (2H, br s), 
3.95 (1H, dd, J = 17.7 and 4.9 Hz), 4.01 (1H, dd, J = 17.7 and 4.9 Hz), 4.12-4.23 (2H, br m), 4.32 (2H, 
br d, J = 6.8 Hz), 4.61 (2H, d, J = 5.9 Hz), 5.25 (1H, ddt, J = 10.7, 1.3 and 1.3 Hz), 5.31 (1H, ddt, J = 
17.0, 1.3 and 1.3 Hz), 5.66 (1H, br d, J = 6.9 Hz), 5.87 (1H, ddt, J = 17.0, 10.7 and 5.9 Hz), 6.29 (1H, 
br t, J = 4.9 Hz), 6.41 (1H, s), 6.50 (1H, br s), 6.92-7.02 (2H, m), 7.02-7.41 (34H, m), 7.49 (1H, d, J 
= 8.2 Hz), 7.56 (1H, d, J = 6.5 Hz), 7.57 (1H, d, J = 6.5 Hz), 7.75 (2H, d, J = 7.4 Hz); 13C NMR 
(CDCl3, 75 MHz)  = 27.8, 29.4, 32.6, 39.7, 41.7, 47.3, 49.4, 51.5, 66.3, 67.1, 67.2, 70.7, 116.8, 117.5, 
118.9, 119.4, 120.1, 124.6, 125.3, 126.5, 126.8, 127.2, 127.8, 128.0, 128.1, 128.8, 129.6, 131.4, 141.4, 
S18 
141.5, 143.8, 144.0, 144.6, 144.7, 148.2, 154.3, 156.1, 159.7, 167.4, 169.3, 170.5, 171.1; HRMS (ESI-
TOF) m/z calcd for C76H66N4NaO9S ([M + Na]+) 1233.4448, found 1233.4451. 
 
[2-(7-{N-[Fmoc-L-Ser(t-Bu)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-acetic 
acid allyl ester (8g) 
 
 
 
 
 
 
White amorphous solid; yield: 87% (207 mg); []21D 36.6 (c 1.02, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 1.09 (9H, s), 2.45 (2H, br m), 3.24-3.42 (3H, m), 3.63 (1H, dt, J = 14.3 and 7.2 Hz), 3.72 
(1H, d, J = 16.0 Hz), 3.76 (1H, d, J = 16.0 Hz), 4.09 (2H, d, J = 5.1 Hz), 4.17 (1H, t, J = 7.0 Hz), 4.25-
4.39 (3H, m), 4.63 (2H, d, J = 5.9 Hz), 5.26 (1H, ddt, J = 10.7, 1.2 and 1.2 Hz), 5.32 (1H, ddt, J = 
17.0, 1.2 and 1.2 Hz), 5.38 (1H, d, J = 7.0 Hz), 5.88 (1H, ddt, J = 17.0, 10.7 and 5.9 Hz), 6.28 (1H, br 
t, J = 5.1 Hz), 6.47 (1H, s), 7.00-7.23 (11H, m), 7.27-7.35 (8H, m), 7.39 (2H, t, J = 7.5 Hz), 7.56 (1H, 
d, J = 6.9 Hz), 7.57 (1H, d, J = 6.9 Hz), 7.61 (1H, d, J = 8.4 Hz), 7.75 (2H, d, J = 7.5 Hz); 13C NMR 
(CDCl3, 75 MHz)  = 27.4, 29.3, 29.8, 39.9, 41.7, 47.2, 49.5, 51.6, 62.8, 66.4, 67.2, 73.8, 117.4, 118.6, 
119.3, 120.1, 124.8, 125.2, 126.0, 126.8, 127.2, 127.8, 128.0, 129.6, 131.3, 141.4, 143.8, 143.9, 144.4, 
144.6, 148.4, 154.0, 155.6, 159.9, 167.5, 169.3, 170.5; HRMS (ESI-TOF) m/z calcd for 
C59H57N3NaO9S ([M + Na]+) 1006.3713, found 1006.3732. 
 
[2-(7-{N-[Fmoc-L-Thr(t-Bu)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-acetic 
acid allyl ester (8h) 
 
 
 
 
 
 
White amorphous solid; yield: 84% (202 mg); []26D 110.1 (c 1.04, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 0.92 (3H, br d, J = 4.4 Hz), 1.03 (9H, br s), 2.19-2.36 (1H, br m), 2.50-2.65 (1H, br m), 
3.17-3.33 (1H, br m), 3.56-3.71 (2H, br m), 3.72 (1H, d, J = 15.7 Hz), 3.77 (1H, d, J = 15.7 Hz), 4.08 
(2H, d, J = 5.2 Hz), 4.13-4.25 (1H, m), 4.21 (1H, t, J = 7.1 Hz), 4.35 (2H, d, J = 7.1 Hz), 4.63 (2H, d, 
J = 6.0 Hz), 5.26 (1H, ddt, J = 10.6, 1.2 and 1.2 Hz), 5.32 (1H, ddt, J = 17.0, 1.2 and 1.2 Hz), 5.50 
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(1H, br d, J = 7.5 Hz), 5.88 (1H, ddt, J = 17.0, 10.6 and 6.0 Hz), 6.28 (1H, t, J = 5.2 Hz), 6.48 (1H, s), 
6.94-7.05 (2H, m), 7.08-7.23 (9H, m), 7.28-7.36 (8H, m), 7.40 (2H, t, J = 7.5 Hz), 7.57-7.66 (3H, m), 
7.76 (2H, d, J = 7.5 Hz); 13C NMR (CDCl3, 75 MHz)  = 20.3, 28.4, 29.3, 39.9, 41.8, 47.3, 49.8, 56.8, 
66.4, 67.2, 67.2, 68.1, 74.5, 116.8, 117.5, 118.5, 119.4, 120.1, 124.9, 125.3, 125.3, 126.2, 126.8, 127.2, 
127.8, 128.0, 129.7, 131.4, 141.4, 143.9, 144.1, 144.6, 144.7, 148.3, 154.3, 156.2, 159.7, 167.3, 169.3, 
170.2; HRMS (ESI-TOF) m/z calcd for C60H59N3NaO9S ([M + Na]+) 1020.3870, found 1020.3878. 
 
[2-(7-{N-[Fmoc-L-Cys(Trt)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-acetic 
acid allyl ester (8i) 
 
 
 
 
 
 
White amorphous solid; yield: 79% (227 mg); []22D 25.2 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 2.13 (1H, dd, J = 11.6 and 7.3 Hz), 2.24-2.37 (2H, m), 2.46 (1H, dt, J = 13.6 and 6.7 Hz), 
3.39 (2H, br t, J = 6.7 Hz), 3.70 (1H, d, J = 15.8 Hz), 3.75 (1H, d, J = 15.8 Hz), 4.08 (2H, d, J = 5.1 
Hz), 4.16-4.36 (4H, m), 4.62 (2H, d, J = 5.9 Hz), 5.25 (1H, ddt, J = 10.7, 1.3 and 1.3 Hz), 5.31 (1H, 
ddt, J = 17.0, 1.3 and 1.3 Hz), 5.41 (1H, d, J = 8.6 Hz), 5.87 (1H, ddt, J = 17.0, 10.7 and 5.9 Hz), 6.24 
(1H, br t, J = 5.1 Hz), 6.48 (1H, s), 6.77 (1H, br s), 6.85 (1H, br d, J = 8.4 Hz), 7.08-7.42 (34H, m), 
7.54 (1H, d, J = 8.4 Hz), 7.59 (1H, d, J = 6.9 Hz), 7.60 (1H, d, J = 6.9 Hz), 7.77 (2H, d, J = 7.5 Hz); 
13C NMR (CDCl3, 75 MHz)  = 29.3, 34.4, 40.0, 41.8, 47.2, 49.7, 50.8, 66.5, 66.9, 67.2, 67.3, 116.8, 
117.7, 118.8, 119.4, 120.1, 124.6, 125.3, 126.3, 126.8, 127.0, 127.2, 127.3, 127.9, 128.0, 128.1, 129.5, 
129.6, 131.3, 141.4, 143.8, 143.9, 144.0, 144.3, 144.6, 148.1, 154.2, 155.5, 159.6, 167.3, 169.3, 169.9; 
HRMS (ESI-TOF) m/z calcd for C74H63N3NaO8S2 ([M + Na]+) 1208.3954, found 1208.3955. 
 
(2-{7-[N-(Fmoc-L-Pro)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid 
allyl ester (8j) 
 
 
 
 
 
 
 
S20 
 
White amorphous solid; yield: 48% (109 mg); []23D 87.9 (c 1.01, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 1.67-2.16 (4H, m), 2.25-2.41 (1.3H, m), 2.50-2.59 (0.7H, m), 3.20-3.39 (1H, m), 3.45-3.53 
(1H, m), 3.54-3.76 (4H, m), 4.06-4.15 (3H, m), 4.20-4.43 (3H, m), 4.59-4.67 (2H, m), 5.26 (1H, ddt, 
J = 10.4, 1.3 and 1.3 Hz), 5.32 (1H, ddt, J = 17.2, 1.3 and 1.3 Hz), 5.82-5.94 (1H, m), 6.31 (1H, br s), 
6.46 (1H, s), 6.59 (0.3H, d, J = 7.2 Hz), 6.74 (0.3H, s), 7.04-7.50 (21.5H, m), 7.56-7.64 (2H, m), 7.75 
(1.4H, d, J = 7.5 Hz), 7.80 (0.6H, d, J = 7.5 Hz),; 13C NMR (CDCl3, 75 MHz)  = 23.5, 24.7, 29.6, 
30.5, 31.7, 39.9, 41.8, 47.1, 47.3, 47.5, 47.7, 49.3, 57.7, 66.5, 67.1, 67.6, 117.1, 117.5, 118.5, 119.5, 
120.1, 120.2, 125.0, 125.3, 125.4, 126.2, 126.8, 127.1, 127.2, 127.8, 128.0, 129.6, 129.7, 131.3, 141.4, 
144.0, 144.2, 144.3, 144.6, 144.7, 145.1, 148.3, 154.2, 154.9, 159.8, 167.4, 169.3, 172.1; HRMS (ESI-
TOF) m/z calcd for C57H51N3NaO8S ([M + Na]+) 960.3295, found 960.3321. 
 
(2-{7-[N-(Fmoc-L-Val)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid 
allyl ester (8k) 
 
 
 
 
 
 
White amorphous solid; yield: 86% (260 mg); []23D 117.3 (c 1.01, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 0.72 (3H, d, J = 6.3 Hz), 0.77 (3H, d, J = 6.5 Hz), 1.73-1.88 (1H, m), 2.23-2.35 (1H, m), 
2.49-2.62 (1H, m), 3.34-3.46 (1H, br m), 3.54 (1H, ddd, J = 13.4, 8.7 and 6.1 Hz), 3.72 (1H, d, J = 
15.5 Hz), 3.78 (1H, d, J = 15.5 Hz), 4.02 (1H, dd, J = 9.3 and 6.5 Hz), 4.09 (2H, d, J = 5.2 Hz), 4.19 
(1H, t, J = 7.1 Hz), 4.30 (1H, dd, J = 10.4 and 7.1 Hz), 4.38 (1H, dd, J = 10.4 and 7.1 Hz), 4.63 (2H, 
d, J = 5.9 Hz), 5.25 (1H, ddt, J = 10.6, 1.2 and 1.2 Hz), 5.28-5.38 (1H, m), 5.32 (1H, ddt, J = 17.0, 1.2 
and 1.2 Hz), 5.88 (1H, ddt, J = 17.0, 10.6 and 5.9 Hz), 6.32 (1H, br s), 6.48 (1H, s), 6.91-7.04 (2H, 
m), 7.09-7.22 (9H, m), 7.27-7.36 (8H, m), 7.39 (2H, t, J = 7.5 Hz), 7.55-7.67 (3H, m), 7.76 (2H, d, J 
= 7.5 Hz); 13C NMR (CDCl3, 75 MHz)  = 17.5, 19.6, 29.4, 31.9, 39.9, 41.7, 47.3, 49.5, 56.8, 66.4, 
67.1, 67.2, 117.0, 117.6, 118.7, 119.4, 120.1, 124.9, 125.2, 126.3, 126.8, 127.2, 127.8, 128.0, 129.6, 
131.4, 141.4, 143.9, 144.0, 144.4, 144.6, 148.3, 154.2, 156.1, 159.7, 167.4, 169.3, 171.7; HRMS (ESI-
TOF) m/z calcd for C57H53N3NaO8S ([M + Na]+) 962.3451, found 962.3468. 
 
(2-{7-[N-(Fmoc-L-Met)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid 
allyl ester (8l) 
S21 
 
 
 
 
 
 
 
White amorphous solid; yield: 83% (196 mg); []21D 76.7 (c 1.02, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 1.63-1.83 (2H, m), 1.89 (3H, s), 2.22-2.39 (3H, m), 2.47-2.60 (1H, br m), 3.37-3.58 (2H, 
m), 3.72 (1H, d, J = 15.6 Hz), 3.77 (1H, d, J = 15.6 Hz), 4.09 (2H, d, J = 5.2 Hz), 4.18 (1H, t, J = 7.0 
Hz), 4.27-4.40 (3H, m), 4.64 (2H, d, J = 5.9 Hz), 5.26 (1H, ddt, J = 10.7, 1.3 and 1.3 Hz), 5.32 (1H, 
ddt, J = 17.0, 1.3 and 1.3 Hz), 5.44 (1H, br d, J = 8.1 Hz), 5.88 (1H, ddt, J = 17.0, 10.7 and 5.9 Hz), 
6.26 (1H, br t, J = 5.2 Hz), 6.48 (1H, s), 6.95-7.05 (2H, m), 7.09-7.24 (9H, m), 7.28-7.37 (8H, m), 
7.40 (2H, t, J = 7.5 Hz), 7.57 (1H, d, J = 6.8 Hz), 7.58 (1H, d, J = 6.9 Hz), 7.64 (1H, d, J = 8.2 Hz), 
7.76 (2H, d, J = 7.5 Hz); 13C NMR (CDCl3, 75 MHz)  = 15.6, 29.4, 29.9, 32.7, 40.0, 41.8, 47.3, 49.4, 
51.1, 66.5, 67.1, 67.2, 116.9, 117.8, 118.9, 119.4, 120.1, 124.7, 125.2, 126.5, 126.9, 127.2, 127.9, 128.0, 
129.6, 131.4, 141.4, 143.8, 144.0, 144.6, 148.2, 154.3, 155.9, 159.6, 167.3, 169.3, 171.4; HRMS (ESI-
TOF) m/z calcd for C57H53N3NaO8S2 ([M + Na]+) 994.3172, found 994.3176. 
 
(2-{7-[N-(Fmoc-L-Leu)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid 
allyl ester (8m) 
 
 
 
 
 
 
White amorphous solid; yield: 91% (563 mg); []27D 94.4 (c 1.02, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 0.41 (3H, br d, J = 5.1 Hz), 0.74 (3H, br d, J = 5.9 Hz), 1.15-1.28 (1H, br m), 1.35-1.52 (2H, 
br m), 2.24-2.37 (1H, m), 2.48-2.60 (1H, br m), 3.27-3.40 (1H, br m), 3.48-3.60 (1H, m), 3.72 (1H, d, 
J = 15.6 Hz), 3.78 (1H, d, J = 15.6 Hz), 4.08 (2H, d, J = 5.2 Hz), 4.15-4.26 (2H, m), 4.27-4.37 (2H, 
m), 4.63 (2H, d, J = 5.9 Hz), 5.26 (1H, ddt, J = 10.6, 1.1 and 1.1 Hz), 5.28-5.38 (2H, m), 5.88 (1H, 
ddt, J = 17.0, 10.6 and 5.9 Hz), 6.43 (1H, br s), 6.49 (1H, s), 7.00 (1H, br s), 7.04 (1H, br d, J = 8.4 
Hz), 7.09-7.21 (9H, m), 7.27-7.36 (8H, m), 7.39 (2H, t, J = 7.5 Hz), 7.57 (1H, d, J = 6.5 Hz), 7.59 (1H, 
d, J = 6.5 Hz), 7.65 (1H, d, J = 8.4 Hz), 7.76 (2H, d, J = 7.5 Hz); 13C NMR (CDCl3, 75 MHz)  = 21.1, 
23.3, 24.6, 29.4, 39.9, 41.7, 42.4, 47.3, 49.3, 50.5, 66.4, 67.1, 67.2, 116.9, 117.6, 118.7, 119.4, 120.1, 
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124.9, 125.3, 126.3, 126.8, 127.2, 127.8, 128.0, 129.6, 131.3, 141.4, 143.9, 144.0, 144.2, 144.6, 148.3, 
154.2, 156.1, 159.7, 167.4, 169.3, 172.6; HRMS (ESI-TOF) m/z calcd for C58H55KN3O8S ([M + K]+) 
992.3347, found 992.3329. 
(2-{7-[N-(Fmoc-L-Ile)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid 
allyl ester (8n) 
 
 
 
 
 
 
White amorphous solid; yield: 85% (195 mg); []22D 110.1 (c 1.01, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 0.67-0.80 (6H, m), 0.81-0.95 (1H, m), 1.32-1.46 (1H, br m), 1.50-1.62 (1H, br m), 2.22-
2.35 (1H, br m), 2.50-2.62 (1H, br m), 3.37-3.47 (1H, m), 3.49-3.59 (1H, m), 3.71 (1H, d, J = 15.6 
Hz), 3.78 (1H, d, J = 15.6 Hz), 4.03 (1H, dd, J = 8.9 and 7.8 Hz), 4.09 (2H, d, J = 5.2 Hz), 4.19 (1H, 
t, J = 7.2 Hz), 4.31 (1H, dd, J = 10.4 and 7.2 Hz), 4.37 (1H, dd, J = 10.4 and 7.2 Hz), 4.63 (2H, d, J = 
6.0 Hz), 5.22-5.36 (1H, m), 5.26 (1H, ddt, J = 10.6, 1.2 and 1.2 Hz), 5.32 (1H, ddt, J = 16.9, 1.2 and 
1.2 Hz), 5.88 (1H, ddt, J = 16.9, 10.6 and 6.0 Hz), 6.23-6.35 (1H, br m), 6.48 (1H, s), 6.92-7.02 (2H, 
m), 7.09-7.24 (9H, m), 7.28-7.43 (10H, m), 7.54-7.66 (3H, m), 7.76 (2H, d, J = 7.5 Hz); 13C NMR 
(CDCl3, 75 MHz)  = 11.4, 15.8, 24.2, 29.4, 38.5, 39.9, 41.8, 47.4, 49.4, 56.2, 66.4, 67.0, 67.2, 117.1, 
117.6, 118.7, 119.4, 120.1, 124.9, 125.2, 126.2, 126.8, 127.2, 127.8, 128.0, 129.6, 131.3, 141.4, 143.9, 
144.0, 144.4, 144.6, 148.3, 154.2, 156.0, 159.8, 167.4, 169.3, 171.8; HRMS (ESI-TOF) m/z calcd for 
C58H55N3NaO8S ([M + Na]+) 976.3608, found 976.3602. 
 
[2-(7-{N-[Fmoc-L-Tyr(t-Bu)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-acetic 
acid allyl ester (8o) 
 
 
 
 
 
White amorphous solid; yield: 73% (188 mg); 
[]26D 17.9 (c 1.04, CHCl3); 1H NMR (CDCl3, 400 MHz)  = 1.32 (9H, s), 2.25-2.42 (2H, m), 2.69 
(1H, dd, J = 12.9 and 5.8 Hz), 2.84 (1H, dd, J = 12.9 and 9.0 Hz), 3.24-3.42 (2H, m), 3.70 (1H, d, J = 
15.7 Hz), 3.75 (1H, d, J = 15.7 Hz), 4.09 (2H, d, J = 5.1 Hz), 4.15 (1H, t, J = 6.9 Hz), 4.22-4.36 (3H, 
m), 4.64 (2H, d, J = 5.9 Hz), 5.26 (1H, ddt, J = 10.7, 1.2 and 1.2 Hz), 5.32 (1H, ddt, J = 17.0, 1.2 and 
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1.2 Hz), 5.39 (1H, br d, J = 8.1 Hz), 5.88 (1H, ddt, J = 17.0, 10.7 and 5.9 Hz), 6.27 (1H, br s), 6.46 
(1H, s), 6.76-6.85 (4H, br s), 7.08-7.23 (10H, m), 7.28-7.36 (9H, m), 7.40 (2H, t, J = 7.5 Hz), 7.47 
(1H, br d, J = 8.0 Hz), 7.55 (1H, d, J = 6.2 Hz), 7.57 (1H, d, J = 6.4 Hz), 7.76 (2H, d, J = 7.5 Hz); 13C 
NMR (CDCl3, 75 MHz)  = 29.0, 29.1, 39.3, 39.9, 41.8, 47.3, 49.3, 53.1, 66.4, 67.1, 67.3, 78.6, 116.9, 
117.7, 118.7, 119.4, 120.1, 124.2, 124.5, 125.2, 125.9, 126.8, 127.2, 127.9, 128.0, 129.6, 130.1, 130.4, 
131.4, 141.4, 143.9, 144.6, 148.1, 154.0, 154.8, 155.4, 159.6, 167.3, 169.3, 171.1; HRMS (ESI-TOF) 
m/z calcd for C65H61N3NaO9S ([M + Na]+) 1082.4026, found 1082.4020. 
 
(2-{7-[N-(Fmoc-L-Phe)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid 
allyl ester (8p) 
 
 
 
 
 
 
White amorphous solid; yield: 81% (194 mg); []20D 58.0 (c 1.03, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 2.24-2.40 (2H, m), 2.75 (1H, dd, J = 12.6 and 5.3 Hz), 2.87 (1H, dd, J = 12.6 and 9.4 Hz), 
3.24-3.43 (2H, br m), 3.70 (1H, d, J = 16.0 Hz), 3.76 (1H, d, J = 16.0 Hz), 4.09 (2H, d, J = 5.0 Hz), 
4.17 (1H, t, J = 7.0 Hz), 4.23-4.40 (3H, m), 4.63 (2H, d, J = 5.9 Hz), 5.26 (1H, ddt, J = 10.6, 1.2 and 
1.2 Hz), 5.32 (1H, ddt, J = 17.0, 1.2 and 1.2 Hz), 5.41 (1H, br d, J = 8.7 Hz), 5.88 (1H, ddt, J = 17.0, 
10.6 and 5.9 Hz), 6.25 (1H, br t, J = 5.0 Hz), 6.46 (1H, s), 6.89 (2H, d, J = 7.3 Hz), 7.08-7.23 (11H, 
m), 7.23-7.36 (11H, m), 7.40 (2H, t, J = 7.5 Hz), 7.48 (1H, d, J = 8.2 Hz), 7.56 (1H, d, J = 6.4 Hz), 
7.57 (1H, d, J = 6.6 Hz), 7.76 (2H, d, J = 7.5 Hz); 13C NMR (CDCl3, 75 MHz)  = 29.2, 39.9, 40.2, 
41.8, 47.3, 49.3, 53.2, 66.5, 67.1, 67.2, 116.7, 117.6, 118.6, 119.5, 120.1, 124.5, 125.2, 125.3, 125.8, 
126.8, 127.2, 127.5, 127.9, 128.0, 128.7, 129.6, 131.3, 135.7, 141.4, 143.8, 143.9, 144.6, 148.2, 153.9, 
155.4, 159.7, 167.3, 169.3, 171.0; HRMS (ESI-TOF) m/z calcd for C61H53KN3O8S ([M + K]+) 
1026.3190, found 1026.3214. 
 
[2-(7-{N-[Fmoc-L-His(MBom)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-
acetic acid allyl ester (8q) 
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White amorphous solid; yield: 70% (193 mg); []23D 58.0 (c 1.01, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 2.21-2.32 (1H, br m), 2.40-2.52 (1H, br m), 2.79 (1H, br dd, J = 14.9 and 6.5 Hz), 2.95 (1H, 
dd, J = 14.9 and 7.6 Hz), 3.20-3.33 (1H, m), 3.52-3.70 (3H, m), 3.77 (3H, s), 4.04 (2H, d, J = 5.2 Hz), 
4.08-4.20 (3H, m), 4.27-4.39 (3H, m), 4.62 (2H, d, J = 5.9 Hz), 4.83 (1H, d, J = 10.9 Hz), 4.90 (1H, 
br d, J = 10.9 Hz), 5.24 (1H, ddt, J = 10.6, 1.2 and 1.2 Hz), 5.30 (1H, ddt, J = 16.9, 1.2 and 1.2 Hz), 
5.57 (1H, br d, J = 7.7 Hz), 5.87 (1H, ddt, J = 16.9, 10.6 and 5.9 Hz), 6.42 (1H, s), 6.60-6.67 (3H, br 
m), 6.83 (2H, d, J = 8.6 Hz), 7.04-7.22 (11H, m), 7.24-7.42 (12H, m), 7.50 (1H, d, J = 8.4 Hz), 7.54 
(1H, d, J = 6.5 Hz), 7.56 (1H, d, J = 6.5 Hz), 7.74 (2H, d, J = 7.5 Hz); 13C NMR (CDCl3, 75 MHz)  
= 27.7, 29.2, 39.8, 41.7, 47.2, 49.2, 51.5, 55.5, 66.4, 67.1, 67.2, 69.4, 72.8, 114.2, 116.8, 117.7, 118.8, 
119.4, 120.1, 124.4, 125.2, 126.3, 126.8, 127.2, 127.9, 128.0, 128.2, 129.6, 129.7, 131.4, 138.5, 141.4, 
143.6, 143.8, 144.5, 148.2, 154.1, 155.4, 159.6, 159.7, 167.4, 169.3, 170.8; HRMS (ESI-TOF) m/z 
calcd for C67H62N5O10S ([M + H]+) 1128.4217, found 1128.4210. 
 
[2-(7-{N-[Fmoc-L-Lys(Boc)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-acetic 
acid allyl ester (8r) 
 
 
 
 
 
 
 
White amorphous solid; yield: 70% (177 mg); []22D 90.0 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 1.02-1.24 (4H, br m), 1.36-1.47 (2H, m), 1.40 (9H, s), 2.23-2.37 (1H, br m), 2.47-2.61 (1H, 
br m), 2.77-2.97 (2H, br s), 3.28-3.40 (1H, br m), 3.53-3.66 (1H, br m), 3.76 (2H, s), 4.09 (2H, d, J = 
5.3 Hz), 4.14-4.24 (1H, m), 4.18 (1H, t, J = 7.1 Hz), 4.32 (2H, d, J = 7.1 Hz), 4.49-4.59 (1H, br s), 
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4.63 (2H, d, J = 5.9 Hz), 5.25 (1H, d, J = 10.7 Hz), 5.32 (1H, dd, J = 17.0 and 1.2 Hz), 5.36-5.48 (1H, 
br m), 5.88 (1H, ddt, J = 17.0, 10.7 and 5.9 Hz), 6.37-6.62 (2H, br s), 6.96-7.06 (2H, m), 7.09-7.21 
(9H, m), 7.24-7.35 (8H, m), 7.40 (2H, t, J = 7.5 Hz), 7.58 (1H, d, J = 6.6 Hz), 7.59 (1H, d, J = 6.9 Hz), 
7.65 (1H, d, J = 8.2 Hz), 7.76 (2H, d, J = 7.5 Hz); 13C NMR (CDCl3, 75 MHz)  = 22.3, 28.5, 29.2, 
29.4, 29.8, 32.5, 39.8, 40.1, 41.7, 47.3, 49.3, 51.5, 66.4, 67.1, 67.2, 76.7, 77.2, 77.4, 77.6, 79.3, 116.9, 
117.7, 118.9, 119.3, 120.1, 124.7, 125.3, 126.4, 126.8, 127.2, 127.8, 128.0, 129.6, 131.4, 141.4, 143.9, 
144.0, 144.6, 148.3, 154.3, 156.1, 159.6, 167.6, 169.3, 171.9; HRMS (ESI-TOF) m/z calcd for 
C63H64N4NaO10S ([M + Na]+) 1091.4241, found 1091.4253. 
 
[2-(7-{N-[Fmoc-L-Arg(Pbf)]-N-(2-tritylsulfanylethyl)amino}coumarin-4-acetylamino)]-acetic 
acid allyl ester (8s) 
 
 
 
 
 
 
 
White amorphous solid; yield: 74% (222 mg); []22D 38.5 (c 1.02, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 1.07-1.28 (1H, br m), 1.33-1.57 (9H, m), 2.05 (3H, s), 2.20-2.27 (1H, m), 2.44 (3H, s), 2.50 
(3H, s), 2.39-2.57 (1H, m), 2.59-2.81 (2H, br m), 2.91 (2H, s), 3.24-3.38 (1H, m), 3.61-3.73 (1H, m), 
3.87-4.10 (3H, m), 4.11-4.21 (2H, m), 4.23-4.42 (3H, m), 4.61 (2H, d, J = 5.7 Hz), 5.22 (1H, ddt, J = 
10.7, 1.3 and 1.3 Hz), 5.31 (1H, ddt, J = 17.0, 1.3 and 1.3 Hz), 5.42-5.80 (2H, br m), 5.67 (1H, d, J = 
9.0 Hz), 5.89 (1H, ddt, J = 17.0, 10.7 and 5.7 Hz), 6.04 (1H, br s), 6.67 (1H, s), 6.94 (1H, s), 6.97 (1H, 
dd, J = 8.4 and 1.6 Hz), 7.08-7.41 (19H, m), 7.53 (1H, d, J = 7.5 Hz), 7.56 (1H, d, J = 7.5 Hz), 7.74 
(2H, dd, J = 7.5 and 3.0 Hz), 7.83 (1H, br d, J = 8.4 Hz), 7.99 (1H, s); 13C NMR (CDCl3, 75 MHz)  
= 12.6, 18.0, 19.4, 23.1, 28.7, 29.3, 39.4, 41.5, 43.3, 47.3, 49.0, 50.8, 66.1, 67.2, 67.3, 86.6, 116.6, 
116.9, 117.7, 118.9, 119.6, 120.2, 120.2, 123.9, 124.8, 125.1, 126.9, 127.2, 127.2, 127.9, 128.0, 129.6, 
131.7, 132.2, 132.9, 138.4, 141.4, 141.5, 143.0, 143.4, 143.8, 144.5, 149.5, 154.0, 155.7, 157.0, 158.9, 
160.0, 168.8, 169.6, 171.3; HRMS (ESI-TOF) m/z calcd for C71H72N6NaO11S2 ([M + Na]+) 1271.4598, 
found 1271.4609. 
 
(2-{7-[N-(Fmoc-L-Trp)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid 
allyl ester (8t) 
 
 
S26 
 
 
 
 
 
 
 
White amorphous solid; yield: 87% (217 mg); []21D 108.1 (c 1.01, CHCl3); 1H NMR (CDCl3, 400 
MHz)  = 2.16 (1H, ddd, J = 12.3, 9.3 and 6.2 Hz), 2.26 (1H, ddd, J = 12.3, 9.0 and 5.6 Hz), 2.94 (1H, 
dd, J = 13.6 and 4.2 Hz), 3.04 (1H, dd, J = 13.6 and 10.3 Hz), 3.17 (1H, ddd, J = 13.3, 9.0 and 6.2 Hz), 
3.43 (1H, ddd, J = 13.3, 9.3 and 5.6 Hz), 3.59 (1H, d, J = 15.7 Hz), 3.67 (1H, d, J = 15.7 Hz), 4.08 
(2H, d, J = 5.2 Hz), 4.22 (1H, t, J = 7.1 Hz), 4.36 (1H, dd, J = 10.4 and 7.1 Hz), 4.39 (1H, dd, J = 10.4 
and 7.1 Hz), 4.53-4.69 (1H, m), 4.64 (2H, d, J = 5.9 Hz), 5.25 (1H, ddt, J = 10.7, 1.2 and 1.2 Hz), 5.31 
(1H, ddt, J = 17.0, 1.2 and 1.2 Hz), 5.59 (1H, br d, J = 8.7 Hz), 5.88 (1H, ddt, J = 17.0, 10.7 and 5.9 
Hz), 6.26 (1H, br t, J = 5.2 Hz), 6.38 (1H, s), 6.72 (1H, s), 6.75-6.84 (1H, br m), 7.01-7.24 (12H, m), 
7.25-7.37 (11H, m), 7.41 (2H, t, J = 7.5 Hz), 7.60 (1H, d, J = 6.7 Hz), 7.61 (1H, d, J = 6.8 Hz), 7.78 
(2H, d, J = 7.5 Hz), 8.03 (1H, s); 13C NMR (CDCl3, 75 MHz)  = 29.2, 29.8, 30.5, 39.6, 41.7, 47.3, 
49.0, 52.3, 66.4, 67.0, 67.1, 110.0, 111.4, 116.0, 117.1, 117.9, 118.4, 119.4, 120.1, 122.1, 123.0, 124.1, 
125.3, 126.8, 127.2, 127.4, 127.9, 127.9, 129.6, 131.3, 136.0, 141.4, 143.6, 143.9, 143.9, 144.6, 148.3, 
153.4, 155.7, 160.0, 167.5, 169.4, 171.9; HRMS (ESI-TOF) m/z calcd for C63H54N4NaO8S ([M + Na]+) 
1049.3560, found 1049.3582. 
 
Typical procedure of removal of an allyl group of 8 
To a stirred mixture of compound 8a (77.0 mg, 85.7 mol) in THF (2mL), N-methylaniline (93.0 L, 
857 mol) and Pd(Ph3P)4 (9.91 mg, 8.57 mol) were added and the reaction mixture was stirred at 
room temperature for 1h. After removal of the solvent in vacuo, the product was purified by column 
chromatography (CHCl3/MeOH  100/0 to 100/7 then 3/2 (v/v)) to yield 9a (53.3 mg, 62.1 mol, 
72 %) as a yellow amorphous solid. 
 
(2-{7-[N-(Fmoc-Gly)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid (9a) 
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Yellow amorphous solid; yield 72% (53.3 mg); 1H NMR (CDCl3, 400 MHz) = 2.41 (2H, t, J = 7.1 
Hz), 3.41-3.63 (4H, m), 3.76 (2H, s), 3.92 (2H, br d, J = 4.2 Hz), 4.15 (1H, t, J = 7.0 Hz), 4.29 (2H, d, 
J = 7.0 Hz), 5.87 (1H, br t, J = 3.9 Hz), 6.51 (1H, s), 6.57 (1H, br s), 6.89 (1H, dd, J = 8.3 and 1.4 Hz), 
6.94 (1H, d, J = 1.4 Hz), 7.09-7.40 (19H, m), 7.54 (2H, d, J = 7.4 Hz), 7.63 (1H, d, J = 8.3 Hz), 7.73 
(2H, d, J = 7.5 Hz); 13C NMR (CDCl3, 75 MHz) = 29.6, 40.6, 41.3, 43.7, 47.1, 48.8, 67.3, 67.6, 
116.7, 117.8, 119.2, 120.2, 124.5, 125.2, 126.9, 127.2, 127.9, 128.1, 129.6, 141.4, 143.0, 143.7, 144.5, 
148.8, 154.3, 156.6, 160.0, 167.7, 168.3, 171.3; HRMS (ESI-TOF) m/z calcd for C51H43N3NaO8S ([M 
+ Na]+) 880.2669, found 880.2656. 
 
(2-{7-[N-(Fmoc-L-Phe)-N-(2-tritylsulfanylethyl)amino]coumarin-4-acetylamino})-acetic acid 
(9p) 
 
 
 
 
 
 
Pale yellow amorphous solid; yield: 57% (217 mg); []28D 46.3 (c 1.01, CHCl3); 1H NMR (CDCl3, 
400 MHz)  = 2.30 (2H, t, J = 7.6 Hz), 2.72 (1H, dd, J = 13.5 and 5.3 Hz), 2.83 (1H, dd, J = 13.5 and 
9.3 Hz), 3.28-3.38 (2H,m), 3.72 (1H, d, J = 15.5 Hz), 3.79 (1H, d, J = 15.5 Hz), 4.07-4.19 (2H, m), 
4.23 (1H, dd, J = 9.3 and 5.3 Hz), 4.28-4.43 (1H, m), 4.31 (1H, dd, J = 7.2 and 10.5 Hz), 4.39 (1H, 
dd, J = 7.2 and 10.5 Hz), 7.10-7.21 (12H, m), 7.28-7.35 (10H, m), 7.40 (2H, dd, J = 7.4 and 8.4 Hz), 
7.50-7.60 (1H, m), 7.55 (2H, t, J = 7.2 Hz), 7.75 (2H, d, J = 7.4 Hz); 13C NMR (CDCl3, 75 MHz)  = 
29.1, 39.7, 40.0, 41.9, 47.1, 49.2, 53.2, 67.2, 67.3, 76.7, 77.2, 77.4, 77.6, 116.5, 117.3, 118.7, 120.1, 
124.4, 125.2, 126.2, 126.8, 127.2, 127.4, 127.9, 127.9, 128.7, 129.6, 135.5, 141.3, 143.5, 143.6, 144.5, 
149.0, 153.6, 155.7, 160.5, 168.5, 171.0, 172.3; HRMS (ESI-TOF) m/z calcd for C58H49N3NaO8S 
([M+Na]+) 970.3138, found 970.3142. 
 
Preparation of SECmide peptide 11 
 
 
 
 
 
 
The protected peptide resin was constructed on NovaSyn® TGR resin (loading: 0.22 mmol/g) using 
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Fmoc SPPS (Acylation: Fmoc amino acid (5.0 equiv), DIC (5.0 equiv) and HOBt·H2O (5.0 equiv) in 
DMF or 9a (2.0 equiv), HATU (1.9 equiv) and DIPEA (1.9 equiv) in DMF for 2 h; Fmoc removal: 
20% (v/v) piperidine DMF for 10 min). The completed resin (150 mg) was treated with TFA–TES–
H2O (95:2.5:2.5, (v/v), 7.5 mL) at room temperature for 2 h. The resin was filtered off and the filtrate 
was directly added to cold Et2O to generate precipitate. The precipitate collected by centrifugation was 
washed with cold Et2O and purified by preparative HPLC to give SECmide peptide 11 (6.2 mg, 25%). 
 
SECmide peptide 11: Analytical HPLC conditions, linear gradient of solvent B in solvent A, 15 to 
25% over 30 min, retention time = 24.6 min. Preparative HPLC condition: linear gradient of solvent 
D in solvent C, 15 to 25% over 30 min. LRMS (ESI-TOF) m/z calcd for ([M + H]+) 906.4, found 906.1. 
 
Preparation of peptide thioester 13 
 
 
 
SECmide peptide 11 (1.5 mg, 1.7 mol) was dissolved in 0.5 M Na phosphate buffer containing 5% 
(v/v) 3-mercaptopropionic acid (MPA), 20 mM tris(2-carboxyethyl)phosphine hydrochloride 
(TCEP·HCl) and 50 mM Na ascorbate (pH 5.0, 1.7 mL). The reaction mixture was incubated at 50 °C 
for 4 h and reaction progress was monitored by analytical HPLC. After completion of the reaction, the 
crude material was purified by preparative HPLC to give 13 (0.89 mg, 1.1 mol, 68% isolated yield). 
Analytical HPLC conditions, linear gradient of solvent B in solvent A, 5 to 30% over 30 min, retention 
time = 18.6 min. Preparative HPLC conditions: linear gradient of solvent B in solvent A, 8 to 18% 
over 30 min. LRMS (ESI-TOF) m/z calcd for ([M + H]+) 677.3, found 677.2. 
 
Preparation of SECmide peptide 14 
 
 
 
 
 
 
The protected peptide resin was constructed on NovaSyn® TGR resin (loading: 0.22 mmol/g) using 
Fmoc SPPS (Acylation: Fmoc amino acid (3.0 equiv), DIC (3.0 equiv) and HOBt·H2O (3.0 equiv) in 
DMF or 9p (2.0 equiv), HATU (1.9 equiv) and DIPEA (1.9 equiv) in DMF for 2 h; Fmoc removal: 
20% (v/v) piperidine in DMF for 10 min). The completed resin (120 mg) was treated with TFA–TES–
H2O (95:2.5:2.5, (v/v), 6.0 mL) at room temperature for 2 h. The resin was filtered off and the filtrate 
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was directly added to cold Et2O to generate precipitate. The precipitate collected by centrifugation was 
washed with cold Et2O and purified by preparative HPLC to give SECmide peptide 14 (4.53 mg, 
16.3%). Analytical HPLC conditions, linear gradient of solvent B in solvent A, 5 to 35% over 30 min, 
retention time = 27.8 min. Preparative HPLC conditions: linear gradient of solvent D in solvent C, 19 
to 28% over 30 min. LRMS (ESI-TOF) m/z calcd for ([M + H]+) 996.4,  found 996.1. 
 
Examination of epimerization during N–S acyl transfer mediated thioesterification 
of SECmide peptide 14 
 
SECmide peptide 14 (0.12 mg, 0.10 mol) was dissolved in 0.5 M Na phosphate buffer containing 
5% (v/v) MPA, 20 mM TCEP·HCl and 50 mM Na ascorbate (pH 5.0, 0.10 mL). The reaction mixture 
was incubated at 50 °C for 8 h and reaction progress was monitored by analytical HPLC. Analytical 
HPLC conditions: linear gradient of solvent B in solvent A, 10 to 30% over 30 min. 
 
Preparation of peptide thioesters S2 and S3 
 
 
 
 
 
 
Typical procedure: On 4-methylbenzhydrylamine (MBHA) resin (0.70 mmol amine/g, 0.36 g, 0.25 
mmol), introduction of Boc-Ala-OH (4.0 equiv) in the presence of DIC (4.0 equiv), HOBt·H2O (4.0 
equiv) and DIPEA (2.0 equiv) in DMF at room temperature for 2 h followed by Boc removal by TFA–
anisole–toluene (50:2:48 (v/v), 30 min) afforded the Boc-Ala-incorporated resin. Next, treatment of 
the resulting resin with S-Tr mercaptopropionic acid (4.0 equiv), DIC (4.0 equiv), HOBt·H2O (4.0 
equiv) and DIPEA (2.0 equiv) in DMF at room temperature for 2 h followed by Trt removal by TFA–
TES (95:5, 10 min) gave HSCH2CH2CO-Ala-MBHA resin. Activated Boc-L-Phe-OH (4.0 equiv) with 
DIC (4.0 equiv), HOBt·H2O (4.0 equiv) and DIPEA (2.0 equiv) in DMF was coupled with 
HSCH2CH2CO-Ala-MBHA resin for 2 h, and the resin was subsequently subjected to Boc removal by 
TFA–anisole–toluene (50:2:48 (v/v), 30 min). On the resulting resin, standard in situ neutralization 
Boc SPPS (Acylation: Boc amino acid (4.0 equiv), DIC (4.0 equiv), HOBt·H2O (4.0 equiv) and DIPEA 
(2.0 equiv) in DMF at room temperature for 2 h; Boc removal: TFA–anisole–toluene (50:2:48 (v/v), 
30 min)) was performed for chain elongation to give a protected peptide resin. The resulting completed 
resin (50 mg) was treated with 1 M TMSOTf–thioanisole in TFA and m-cresol (100/5 (v/v)) at 4 °C 
for 2 h. After filtration of the resin, cooled Et2O was added to the filtrate to give precipitate. The 
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formed precipitate was collected by centrifugation and thoroughly washed with Et2O to afford crude 
peptide thioester. The crude peptide thioester was purified by preparative HPLC to give the purified 
peptide S2 (2.0 mg, 9.4%). 
 
Peptide thioester S2: Analytical HPLC conditions, linear gradient of solvent B in solvent A, 10 to 30% 
over 30 min, retention time = 24.1 min. Preparative HPLC conditions: linear gradient of solvent B in 
solvent A, 10 to 30% over 30 min. LRMS (ESI-TOF) m/z calcd for ([M + H]+) 837.4, found 837.1. 
 
Peptide thioester S3 (2.0 mg, 9.2%): Analytical HPLC conditions, linear gradient of solvent B in 
solvent A, 10 to 30% over 30 min, retention time = 27.1 min. Preparative HPLC conditions: linear 
gradient of solvent B in solvent A, 10 to 30% over 30 min. LRMS (ESI-TOF) m/z calcd for ([M + H]+) 
837.4, found 837.1. 
 
Preparation of peptide thioesters S4 and S5 
 
 
 
 
 
 
Typical procedure: Peptide thioester S2 (0.94 mg, 1.0 mol) was dissolved in 6 M guanidine·HCl–0.1 
M Na phosphate buffer containing 2% (v/v) MPA (pH 7.3, 1.0 mL). The reaction mixture was 
incubated at 37 °C for 1 h and reaction progress was monitored by analytical HPLC. After 1 h of the 
reaction, the crude material was purified by preparative HPLC to give S4 (0.10 mg, 0.13 mol, 13% 
isolated yield). 
 
Peptide thioester S4: Analytical HPLC conditions, linear gradient of solvent B in solvent A, 10 to 30% 
over 30 min, retention time = 27.2 min. Preparative HPLC conditions: linear gradient of solvent B in 
solvent A, 15 to 35% over 30 min. LRMS (ESI-TOF) m/z calcd for ([M + H]+) 767.3, found 767.1. 
 
Peptide thioester S5 (0.25 mg, 0.33 mol, 33% isolated yield): Analytical HPLC conditions, linear 
gradient of solvent B in solvent A, 10 to 30% over 30 min, retention time = 29.8 min. Preparative 
HPLC conditions: linear gradient of solvent B in solvent A, 15 to 35% over 30 min. LRMS (ESI-TOF) 
m/z calcd for ([M + H]+) 767.3, found 767.2. 
 
Preparation of SEAlide peptide 16 
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The protected peptide resin was constructed on NovaSyn® TGR resin (loading: 0.22 mmol/g) using 
Fmoc SPPS (Acylation: Fmoc amino acid (4.0 equiv), DIC (4.0 equiv) and HOBt·H2O (4.0 equiv) in 
DMF or 4-[(Fmoc-Gly -2-tritylsulfanylethyl)amino]benzoic acid (2.0 equiv), HATU (1.9 equiv) and 
DIPEA (1.9 equiv) in DMF for 2 h; Fmoc removal: 20% (v/v) piperidine in DMF for 10 min). The 
completed resin (100 mg) was treated with TFA–TES–H2O (95:2.5:2.5, (v/v), 5.0 mL) at room 
temperature for 2 h. The resin was filtered off and the filtrate was directly added to cold Et2O to 
generate precipitate. The precipitate collected by centrifugation was washed with cold Et2O and 
purified by preparative HPLC to give SEAlide peptide 16 (3.1 mg, 11%). Analytical HPLC conditions, 
linear gradient of solvent B in solvent A, 10 to 60% over 30 min, retention time = 11.2 min. Preparative 
HPLC conditions: linear gradient of solvent D in solvent C, 15 to 25% over 30 min. LRMS (ESI-TOF) 
m/z calcd for ([M + H]+) 824.4, found 824.2. 
 
Preparation of N-terminal cysteinyl peptide 17 
 
 
The protected peptide resin was constructed on NovaSyn® TGR resin (loading: 0.22 mmol/g) using 
Fmoc SPPS (Acylation: Fmoc amino acid (3.0 equiv), DIC (3.0 equiv) and HOBt·H2O (3.0 equiv) in 
DMF) in DMF for 2 h; Fmoc removal: 20% (v/v) piperidine in DMF for 10 min). The completed resin 
(200 mg) was treated with TFA–m-cresol–thioanisole–H2O–1,2-ethanedithiol (80:5:5:5:5, (v/v), 10 
mL) at room temperature for 2 h. The resin was filtered off and the filtrate was directly added to cold 
Et2O to generate precipitate. The precipitate collected by centrifugation was washed with cold Et2O 
and purified by preparative HPLC to give N-terminal cysteinyl peptide 17 (14 mg, 37%). Analytical 
HPLC conditions, linear gradient of solvent B in solvent A, 1 to 30% over 30 min, retention time = 
11.0 min. Preparative HPLC conditions: linear gradient of solvent B in solvent A, 1 to 13% over 30 
min. LRMS (ESI-TOF) m/z calcd for ([M + H]+) 753.4, found 753.2. 
NCL between SECmide peptide 11, 14 or SEAlide peptide 16 and N-terminal 
cysteinyl peptide 17 
NCL between SECmide peptide 11 or SEAlide peptide 16 and N-terminal cysteinyl peptide 17: 
NCL between SECmide peptide 11 or SEAlide peptide 16 and N-terminal cysteinyl peptide 17 was 
performed in 0.1 M HEPPS buffer containing 40 mM additive and 30 mM TCEP·HCl (pH 7, 100 L,1 
mM each peptide) at 37 °C.  
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Ligation product 18: Analytical HPLC conditions, linear gradient of solvent B in solvent A, 5 to 35% 
over 30 min, retention time = 18.6 min. LRMS (ESI-TOF) m/z calcd for ([M + 2H]2+) 662.3, found 
662.4. 
 
NCL between SECmide peptide 14 and N-terminal cysteinyl peptide 17: 
NCL between SECmide peptide 14 and N-terminal cysteinyl peptide 17 was performed in 0.1 M 
HEPPS buffer containing 40 mM additive and 30 mM TCEP·HCl (pH 7, 100 L,1 mM each peptide) 
at 50 °C.  
 
Ligation product 19: Analytical HPLC conditions, linear gradient of solvent B in solvent A, 5 to 35% 
over 30 min, retention time = 21.7 min. LRMS (ESI-TOF) m/z calcd for ([M + 2H]2+) 707.3, found 
707.3. 
 
Preparation of S6 and S7 
 
 
Typical procedure: Peptide thioester S2 (1.1 mg, 1.0 mol) and N-terminal cysteinyl peptide 17  (1.2 
mg, 1.0 mol) was dissolved in 0.1 M HEPPS buffer containing 40 mM MPAA and 30 mM TCEP·HCl 
(pH 7, 100 L,1 mM each peptide) at 37 °C. The reaction mixture was incubated for 1.5 h and reaction 
progress was monitored by analytical HPLC. After 1.5 h of the reaction, the crude material was 
purified by preparative HPLC to give S6 (0.34 mg, 0.24 mol, 24% isolated yield). 
 
S6 (X = L-Phe): Analytical HPLC conditions, linear gradient of solvent B in solvent A, 5 to 35% over 
30 min, retention time = 21.1 min. Preparative HPLC conditions: linear gradient of solvent B in solvent 
A, 5 to 35% over 30 min. LRMS (ESI-TOF) m/z calcd for ([M + 2H]2+) 707.8, found 707.4. 
 
S7 (X = D-Phe, 0.25 mg, 0.078 mol, 7.8% isolated yield): Analytical HPLC conditions, linear 
gradient of solvent B in solvent A, 5 to 35% over 30 min, retention time = 23.7 min. Preparative HPLC 
conditions: linear gradient of solvent B in solvent A, 5 to 35% over 30 min. LRMS (ESI-TOF) m/z 
calcd for ([M + 2H]2+) 707.8, found 707.5. 
 
Kinetics measurement 
 
Ligation of SECmide peptide 11 (0.020 mol) and cysteine·HCl (4.0 mol) were performed in 0.3 M 
additive aq. containing 40 mM TCEP·HCl and 30 mM MPAA (pH 7.0 or pH 6.0, 200 L, SECmide 
S33 
peptide: 0.10 mM, cysteine: 20 mM) at 37 °C. Fluorescence intensity of S1 was measured (ex: 373 
nm; em: 465 nm) and it was defined as time = 0 min. Then, the fluorescence of the reaction mixture 
was recorded at 1, 2, 3, 6 and 12 h. Half-life of 11 was estimated based on GraphPad Prism 5 software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR and 13C NMR spectra 
1H NMR spectrum of 5 
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13C NMR spectrum of 5 
 
1H NMR spectrum of 6 
 
S35 
 
 
13C NMR spectrum of 6 
 
 
1H NMR spectrum of 7 
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13C NMR spectrum of 7 
 
 
1H NMR spectrum of 3 
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13C NMR spectrum of 3 
 
 
1H NMR spectrum of 8a 
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13C NMR spectrum of 8a 
 
 
1H NMR spectrum of 8b 
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13C NMR spectrum of 8b 
 
 
1H NMR spectrum of 8c 
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13C NMR spectrum of 8c 
 
 
1H NMR spectrum of 8d 
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13C NMR spectrum of 8d 
 
 
1H NMR spectrum of 8e 
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13C NMR spectrum of 8e 
 
 
1H NMR spectrum of 8f 
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13C NMR spectrum of 8f 
 
 
1H NMR spectrum of 8g 
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13C NMR spectrum of 8g 
 
 
1H NMR spectrum of 8h 
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13C NMR spectrum of 8h 
 
 
1H NMR spectrum of 8i 
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13C NMR spectrum of 8i 
 
 
1H NMR spectrum of 8j 
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13C NMR spectrum of 8j 
 
 
1H NMR spectrum of 8k 
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13C NMR spectrum of 8k 
 
 
1H NMR spectrum of 8l 
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13C NMR spectrum of 8l 
 
 
1H NMR spectrum of 8m 
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13C NMR spectrum of 8m 
 
 
1H NMR spectrum of 8n 
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13C NMR spectrum of 8n 
 
 
1H NMR spectrum of 8o 
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13C NMR spectrum of 8o 
 
 
1H NMR spectrum of 8p 
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13C NMR spectrum of 8p 
 
 
1H NMR spectrum of 8q 
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13C NMR spectrum of 8q 
 
 
1H NMR spectrum of 8r 
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13C NMR spectrum of 8r 
 
 
1H NMR spectrum of 8s 
 
S56 
 
 
13C NMR spectrum of 8s 
 
 
1H NMR spectrum of 8t 
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13C NMR spectrum of 8t 
 
 
1H NMR spectrum of 9a 
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13C NMR spectrum of 9a 
 
 
1H NMR spectrum of 9p 
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13C NMR spectrum of 9p 
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